SNGX: Updated IIS Data Shows 75% Response Rate and Three Complete Responses
On April 14, 2025, Soligenix, Inc. (SNGX) announced interim results from the ongoing, open label, investigator initiated study (IIS) evaluating...
185 Views
SNGX: Preclinical Data Shows CiVax Booster Induces Broad Protection Against COVID-19
On March 21, 2025, Soligenix, Inc. (SNGX) announced financial results for 2024 and provided a business update. The company recently announced a...
161 Views
SNGX: Presentation Highlights HyBryte Potential in CTCL
In January 2025, Dr. Neal Bhatia presented at two dermatology conferences on the off-label use of photodynamic therapy. Dr. Bhatia is the Director...
228 Views
SNGX: Additional Positive Outcomes in Investigator-Initiated Study of HyBryte in CTCL
On January 14, 2025, Soligenix, Inc. (SNGX) announced additional interim data from the open-label, investigator-initiated study (IIS) testing...
213 Views
SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway
On December 16, 2024, Soligenix, Inc. (SNGX) announced it has opened patient enrollment for the confirmatory Phase 3 FLASH2 (Fluorescent Light...
262 Views